Sesen Bio slides on plans to conduct another cancer drug trial

Carisma Therapeutics

09/12/2021 16:20

** Drug developer's shares  SESN.O  fall nearly 16% to 91
cents 
    ** Co says it plans to conduct an additional trial of its
bladder cancer drug, Vicineum, in order to re-submit the
marketing application for the drug to the FDA  urn:newsml:reuters.com:*:nBw6lxLlqa
    ** The FDA declined to approve the drug in August, saying it
could not approve the drug's marketing application in its
current form  urn:newsml:reuters.com:*:nL4N2PK3Q4
    ** Co says it will conduct a clinical trial comparing the
drug against intravesical chemotherapy
    ** Including Thursday's losses, stock down over 30% YTD 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))